Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Amyris Shares Rose as Much as 12.5% Today

By Maxx Chatsko - Updated Feb 3, 2020 at 11:34AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Another year, another set of financing transactions that provide a lifeline to the struggling company.

What happened

Shares of Amyris (AMRS 4.32%) jumped more than 12% today after the company announced two financial transactions that will affect its balance sheet. 

First, existing shareholder Foris Ventures exercised existing warrants to convert roughly $70 million in debt into common stock. That move will dilute shareholders and remove that portion of the debt from the company's balance sheet. Second, Amyris raised $42 million in a combination of debt and stock sales from various shareholders. 

As of 11:38 a.m. EST on Monday, the small-cap stock had settled to a 10.3% gain.

A man holding a cutout of an arrow pointing up.

Image source: Getty Images.

So what

The stock is jumping today because investors are interpreting the transactions as the latest lifeline for the struggling company. Amyris has been walking a tightrope with its balance sheet since at least 2015 and has been forced to rely on numerous debt arrangements, stock offerings, reverse stock splits, and the like to stay listed on the Nasdaq exchange and keep the lights on.

To be blunt, the financing is less a vote of confidence in the industrial biotech company and more likely a bit of corporate raiding. The business has missed "only" a handful of debt payments over the years, but tends to come up with new financing from new financers to kick the can down the road. Holders of debt notes can collect double-digit interest rates in the process. 

Of course, it all comes at the expense of individual shareholders, who have suffered five-year losses of 90%. Meanwhile, Amyris reported an operating loss of $90 million and a net loss of $163 million in the first nine months of 2019. 

Now what

Amyris has a promising cosmetics portfolio, but has not been successful in a dozen or so other ingredients produced from its platform, and it suffers from terrible management. Investors hoping that the company can live up to its lofty promises should consider the long, troubled history of execution. Simply put, this stock doesn't belong in your portfolio.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Amyris, Inc. Stock Quote
Amyris, Inc.
AMRS
$1.93 (4.32%) $0.08

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
316%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/02/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.